  |
|
Laboratory of Pharmaceutical Pharmacology (founded 2001) aims to discover novel drug targets, investigates the molecular mechanisms of the pharmacological action of drugs, as well as tests the biological activity of novel compounds. The applied research projects are implemented in close collaboration with the pharmaceutical industry. The research directions include cardiovascular, CNS and molecular pharmacology. Research methods cover in vivo and in vitro tests, including cell culture, isolated organs and mitochondria, gene expression analysis.
Selected recent publications
- Zvejniece L, Stelfa G, Vavers E, Kupats E, Kuka J, Svalbe B, Zvejniece B, Albert-Weissenberger C, Sirén AL, Plesnila N, Dambrova M. Skull Fractures Induce Neuroinflammation and Worsen Outcomes after Closed Head Injury in Mice. J. Neurotrauma. 2020; 37(2): 295-304. doi: 10.1089/neu.2019.6524
- Vaara M, Vaara T, Kuka J, Sevostjanovs E, Grinberga S, Dambrova M, Liepinsh E. Excretion of the Polymyxin Derivative NAB739 in Murine Urine. Antibiotics (Basel). 2020; 9(4):E143. doi: 10.3390/antibiotics9040143
- Makrecka-Kuka M, Sevostjanovs E, Vilks K, Volska K, Antone U, Kuka J, Makarova E, Pugovics O, Dambrova M, Liepinsh E. Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues. Sci Rep. 2017; 7(1):17528. doi: 10.1038/s41598-017-17797-x
- Dambrova M, Makrecka-Kuka M, Vilskersts R, Makarova E, Kuka J, Liepinsh E. Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacol Res. 2016 113(Pt B):771-780. doi: 10.1016/j.phrs.2016.01.019
- Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S, Hartmane D, Pugovics O, Erglis A, Liepinsh E. Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels. Exp Clin Endocrinol Diabetes 2016; 124(4):251-6. doi: 10.1055/s-0035-1569330
Selected recent patents
- Zvejniece L., Dambrova M., Svalbe B., Vavers E., Kalvins I., Veinbergs G., Stonans I., Misane I., Vorona M., Cernobrovijs A. Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures. US10105348 (B2) – 2018-10-23.
- Zvejniece L., Dambrova M., Svalbe B., Vavers E., Kalvins I., Veinbergs G., Stonans I., Misane I., Vorona M., Cernobrovijs A. Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures. JP6470870 (B2) – 2019-01-25.
- Zvejniece L., Dambrova M., Svalbe B., Vavers E., Kalvins I., Veinbergs G., Stonans I., Misane I., Vorona M., Cernobrovijs A. Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures. UA120886 (C) – 2020-02-25.
- Zvejniece L., Dambrova M., Svalbe B., Vavers E., Kalvins I., Veinbergs G., Stonans I., Misane I., Vorona M., Cernobrovijs A. Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures. TW I643617 (B) – 2018-12-11.
- Liepins E., Dambrova M., Makrecka-Kuka M., Kuka J., Makarova E., Sevostjanovs E. Metode insulīna rezistences diagnostikai, izmantojot acilkarnitīnu koncentrāciju noteikšanu asinīs. LV15206 (B1) – 2017-07-20.